LABS MediPharm Labs

La società farmaceutica europea STADA entra in una partnership esclusiva con MediPharm Labs per la cannabis medica

La società farmaceutica europea STADA entra in una partnership esclusiva con MediPharm Labs per la cannabis medica
EN
08/10/2020

Underlying

LABSMediPharm Labs

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MediPharm Labs

 PRESS RELEASE
Free
LABS MEDIPHARM LABS

MediPharm Strengthens Global Position in Q2 2025, with 14% Revenue Gro...

MediPharm Strengthens Global Position in Q2 2025, with 14% Revenue Growth and 50% Increase in International Medical Cannabis Q2 Revenue of $11.8 Million, an Increase of 14% over Q2 202450% Growth in Revenue for International Medical CannabisInternational Medical sales now 57% of Total RevenueCash Balance of $10.4 Million at the end of Q2, Increased from $8.4 Million in Q1 2025Management to Host Conference Call / Webcast on August 14th, 2025 at 10:00 am ET TORONTO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: ) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or t...

August 14, 2025 1 EN
 PRESS RELEASE
Free
LABS MEDIPHARM LABS

MediPharm Labs Sets Date to Report Second Quarter 2025 Financial Resul...

MediPharm Labs Sets Date to Report Second Quarter 2025 Financial Results TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: ) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it will release its second quarter financial results for the three and six months ended June 30th, 2025, before markets open on Thursday, August 14th, 2025. MediPharm Labs executive management team will also host a conference call and webcast on Thursday, August 14th, 2025 at 10:0...

August 11, 2025 1 EN
 PRESS RELEASE
Free
LABS MEDIPHARM LABS

MediPharm Labs Expands Leading CBN Oil Portfolio with The Launch of Ne...

MediPharm Labs Expands Leading CBN Oil Portfolio with The Launch of New Nighttime Inhaler TORONTO, July 24, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company"), a pharmaceutical company specializing in precision-based cannabinoids, is pleased to announce it has launched the new Shake & Puff CBN THC Nighttime Inhaler in Canada. This innovative product expands MediPharm’s leading CBN oil product portfolio and builds on the success of the Company’s THC Inhaler introduced earlier this year. The new metered dose ...

July 24, 2025 1 EN
 PRESS RELEASE
Free
LABS MEDIPHARM LABS

MediPharm Announces Voting Results from the 2025 Annual and Special Me...

MediPharm Announces Voting Results from the 2025 Annual and Special Meeting of Shareholders TORONTO, June 17, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm” or the “Company”), a pharmaceutical company specialized in precision-based cannabinoids, today announced the results of matters voted on at its annual and special meeting (the “Meeting”) of holders of common shares ("Shareholders") held today. There were 146 Shareholders represented virtually or by proxy at the Meeting holding an aggregate of 210,726,733 common shares, representing 50...

June 17, 2025 1 EN
 PRESS RELEASE
Free
LABS MEDIPHARM LABS

MediPharm Cautions Shareholders To Await Final Results of Annual and S...

MediPharm Cautions Shareholders To Await Final Results of Annual and Special Meeting TORONTO, June 16, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm” or the “Company”), a pharmaceutical company specialized in precision-based cannabinoids, wishes to respond to a misleading press release published earlier today by Apollo Technology Capital Corporation (“Apollo”) prematurely claiming that it considers the results of the annual and special meeting of shareholders scheduled to take place at 3:00 p.m. today (the “Meeting”) to be a clear victory ...

June 16, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch